Author Disclosure Statement
T1D, Nordisk, Diabetes
DIABETES
The pivotal trial investigators received funding and support from Medtronic (Northridge, CA) to conduct the study at each of their respective centers. G.P.F., conducts research supported by Medtronic, Dexcom, Abbott Diabetes Care, Tandem Diabetes Care, Insulet Corporation, Beta Bionics and Lilly, and has served as a speaker/consultant/advisory board member for Medtronic, Dexcom, Abbott Diabetes Care, Tandem Diabetes Care, Insulet Corporation, Beta Bionics, and Lilly. D.I.S. serves as advisory board member for Medtronic, R.P-B. has received research support from Medtronic and other consulting fees from Novo Nordisk, Bayer, Roche Diabetes Care, Averitas Pharma, Inc., and Nevro. J.R.T has served as advisory board and data safety monitoring board member to Medtronic and provided editorial support to Boehringer Ingelheim.J.R.T. is President of the Arkansas Diabetes and Endocrinology Center and Medical Investigations, Inc., and has received research support and speaking fees from Medtronic and Lilly, research support from Novo Nordisk and Inversago Pharma, and speaking fees from Bayer. M.S.K. has served as advisory board member to Quest Diagnostics and Corcept Therapeutics and received research support from Abbott Diabetes Care, Aeterna Zentaris, Allergan Sales, LLC., Amgen, Ascendis Pharma, AstraZeneca, 89Bio, Inc., Biolinq, Inc., Corcept Therapeutics, Dexcom, Lily, Giliad Sciences, Inc., Inventiva BioPharma, Ionis Pharmaceuticals, Insulet Corporation, Kowa Research Institute, Inc., Lumos Pharma, Mannkind Corporation, Medtronic, Metacrine, Inc., NGM Biopharmaceuticals, Pfizer, Reata Pharmaceuticals, Regenacy Pharmaceuticals, Inc., Sagimet Biosciences, Senseonics, Inc., Tandem Diabetes Care, Tolerion, Inc., Vertex Pharmaceuticals, Inc., Zydus Discovery and Zydus Therapeutics Inc., M.P.C. discloses that Diablo Clinical Research has received funding to conduct research from Medtronic, Dexcom, Senseonics, Novo Nordisk, Lilly, Pfizer, Biolinq, Inc., and GraphWear.B.A.B. has served as advisory board member for Medtronic, Novo Nordisk, and Lilly, and conducted studies sponsored by Medtronic, Tandem Diabetes Care, Insulet Corporation, the JDRF, and National Institutes of Health. C.P. has no competing financial disclosures. J.L.S. serves or has served on advisory panels for Bigfoot Biomedical, Cecelia Health, Insulet Corporation, Medtronic, StartUp Health Diabetes Moonshot, and Vertex Pharmaceuticals; has served as consultant to Abbott Diabetes Care, Bigfoot Biomedical, Insulet Corporation, Medtronic and Zealand Pharma. The Yale School of Medicine has received research support for J.L.S. from Abbott Diabetes Care, JAEB Center for Health Research, the JDRF, Insulet Corporation, Medtronic, the National Institutes of Health and ProventionBio. K.B.K is an employee of MannKind Corporation and has received research support from Medtronic.The MiniMed™ 780G pump with Guardian™ 4 Sensor is approved by the Food and Drug Administration for individuals ≥7 years of age with T1D. The MiniMed™ 780G system includes technology developed by DreaMed Diabetes (Petah Tikvah, Israel).